Why, when, and how to prevent hepatitis B virus reactivation in cancer patients undergoing chemotherapy

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 9, Issue 5, 2011, Pages 465-477

  Keam, Bhumsuk ^a   Lee, Jeong Hoon ^a   Im, Seock Ah ^a   Yoon, Jung Hwan ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Cancer; Chemotherapy; Hepatitis B virus; Reactivation

Indexed keywords

ADEFOVIR; ALEMTUZUMAB; ALKYLATING AGENT; ANTHRACYCLINE; ANTINEOPLASTIC ANTIBIOTIC; BEVACIZUMAB; CETUXIMAB; CORTICOSTEROID; ENTECAVIR; ERLOTINIB; EVEROLIMUS; GEFITINIB; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; IMATINIB; LAMIVUDINE; MONOCLONAL ANTIBODY; PLATINUM; RITUXIMAB; SORAFENIB; SUNITINIB; TACROLIMUS; TAXANE DERIVATIVE; TRASTUZUMAB; VINCA ALKALOID;

ANTIBODY SCREENING; ANTIVIRAL THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOEMBOLIZATION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; GRAFT REJECTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FUNCTION TEST; LIVER INJURY; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; VIRUS LOAD; VIRUS PATHOGENESIS; VIRUS REACTIVATION; VIRUS REPLICATION;

EID: 79955875687     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2011.0045     Document Type: Review

References (116)

1. Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 2004;350:1118-1129. (Pubitemid 38298992)
2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11:97-107. (Pubitemid 38365759)
3. Kane M. Global programme for control of hepatitis B infection. Vaccine 1995;13(Suppl 1):S47-49.
4. Lee DH, Kim JH, Nam JJ, et al. Epidemiological findings of hepatitis B infection based on 1998 National Health and Nutrition Survey in Korea. J Korean Med Sci 2002;17:457-462.
5. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006;43:209-220.
6. Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008;148:519-528. (Pubitemid 351665421)
7. Kohrt HE, Ouyang DL, Keeffe EB. Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther 2006;24:1003-1016. (Pubitemid 44386525)
8. Kusumoto S, Tanaka Y, Mizokami M, et al. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 2009;90:13-23.
9. Lok AS, Lai CL, Wu PC, et al. Hepatitis B virus infection in Chinese families in Hong Kong. Am J Epidemiol 1987;126:492-499.
10. Lok AS, Liang RH, Chiu EK, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991;100:182-188.
11. Jilg W, Hottentrager B, Weinberger K, et al. Prevalence of markers of hepatitis B in the adult German population. J Med Virol 2001;63:96-102. (Pubitemid 32142265)
12. Nakamura Y, Motokura T, Fujita A, et al. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991. Cancer 1996;78:2210-2215.
13. Wands JR, Chura CM, Roll FJ, et al. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 1975;68:105-112.
14. Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000;62:299-307.
15. Yeo W, Chan PK, Hui P, et al. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol 2003;70:553-561. (Pubitemid 36734719)
16. Lubel JS, Testro AG, Angus PW. Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Intern Med J 2007;37:705-712. (Pubitemid 47481164)
17. Lau JY, Bird GL, Gimson AE, et al. Treatment of HBV reactivation after withdrawal of immunosuppression. Lancet 1991;337:802.
18. Vento S, Cainelli F, Longhi MS. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol 2002;3:333-340. (Pubitemid 34661982)
19. Hoofnagle JH, Dusheiko GM, Schafer DF, et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982;96:447-449. (Pubitemid 12139868)
20. Xunrong L, Yan AW, Liang R, et al. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy - pathogenesis and management. Rev Med Virol 2001;11:287-299. (Pubitemid 33009970)
21. Chou CK, Wang LH, Lin HM, et al. Glucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells. Hepatology 1992;16:13-18.
22. Tur-Kaspa R, Burk RD, Shaul Y, et al. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci U S A 1986;83:1627-1631. (Pubitemid 16018617)
23. Kumagai K, Takagi T, Nakamura S, et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol 1997;8(Suppl 1):107-109.
24. European Association for the Study of the Liver. EASL clinical practice guidelines. Management of chronic hepatitis B [in French]. Gastroenterol Clin Biol 2009;33:539-554.
25. Lee KS, Kim DJ, Korean Association for the Study of the Liver Guidelines Committee. [Management of chronic hepatitis B]. Korean J Hepatol 2007;13:447-488 [in Korean].
26. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008;2:263-283.
27. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-662.
28. Yeo W, Lam KC, Zee B, et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol 2004;15:1661-1666. (Pubitemid 39562607)
29. Lau GK. Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int 2008;2:152-162. (Pubitemid 351650143)
30. Lau GK, Leung YH, Fong DY, et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 2002;99:2324-2330. (Pubitemid 34525416)
31. Jang JW, Choi JY, Bae SH, et al. Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J Hepatol 2004;41:427-435. (Pubitemid 39158752)
32. Zhong S, Yeo W, Schroder C, et al. High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepat 2004;11:55-59. (Pubitemid 38221618)
33. Yeo W, Zee B, Zhong S, et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004;90:1306-1311. (Pubitemid 38586252)
34. Jang JW, Choi JY, Bae SH, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemolipiodolization. Hepatology 2006;43:233-240.
35. Nagamatsu H, Kumashiro R, Itano S, et al. Investigation of associating factors in exacerbation of liver damage after chemotherapy in patients with HBV-related HCC. Hepatol Res 2003;26:293-301. (Pubitemid 37184518)
36. Liao CA, Lee CM, Wu HC, et al. Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma. Br J Haematol 2002;116:166-169.
37. Picardi M, Pane F, Quintarelli C, et al. Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations. Haematologica 2003;88:1296-1303. (Pubitemid 37456385)
38. Carman WF, Fagan EA, Hadziyannis S, et al. Association of a precore genomic variant of hepatitis B virus with fulminant hepatitis. Hepatology 1991;14:219-222.
39. Hui CK, Bowden S, Jackson K, et al. Clinical significance of intrahepatic hepatitis B virus covalently closed circular DNA in chronic hepatitis B patients who received cytotoxic chemotherapy. Blood 2005;105:2616-2617. (Pubitemid 40387069)
40. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol 2005;42:302-308. (Pubitemid 40254242)
41. Kim MK, Ahn JH, Kim SB, et al. Hepatitis B reactivation during adjuvant anthracycline-based chemotherapy in patients with breast cancer: a single institution's experience. Korean J Intern Med 2007;22:237-243.
42. Yeo W, Ho WM, Hui P, et al. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat 2004;88:209-215. (Pubitemid 40137299)
43. Nagamatsu H, Itano S, Nagaoka S, et al. Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy. Am J Gastroenterol 2004;99:2369-2375. (Pubitemid 40039368)
44. Yeo W, Hui EP, Chan AT, et al. Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine. Am J Clin Oncol 2005;28:379-384. (Pubitemid 41099543)
45. Alexopoulos CG, Vaslamatzis M, Hatzidimitriou G. Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours. Br J Cancer 1999;81:69-74. (Pubitemid 29415493)
46. Niscola P, Del Principe MI, Maurillo L, et al. Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy. Leukemia 2005;19:1840-1841. (Pubitemid 41486166)
47. Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother 2005;11:189-191. (Pubitemid 41216450)
48. Westhoff TH, Jochimsen F, Schmittel A, et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003;102:1930. (Pubitemid 37022596)
49. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001;344:68-69. (Pubitemid 32064857)
50. Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009;27:605-611.
51. Tsutsumi Y, Tanaka J, Kawamura T, et al. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma. Ann Hematol 2004;83:58-60. (Pubitemid 38088239)
52. Dai MS, Chao TY, Kao WY, et al. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol 2004;83:769-774.
53. Pei SN, Chen CH, Lee CM, et al. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 2009;89:255-262.
54. Yamagata M, Murohisa T, Tsuchida K, et al. Fulminant B hepatitis in a surface antigen and hepatitis B DNA-negative patient with diffuse large B-cell lymphoma after CHOP chemotherapy plus rituximab. Leuk Lymphoma 2007;48:431-433. (Pubitemid 46994901)
55. Sera T, Hiasa Y, Michitaka K, et al. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med 2006;45:721-724. (Pubitemid 44027603)
56. Law JK, Ho JK, Hoskins PJ, et al. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 2005;46:1085-1089. (Pubitemid 40975032)
57. Kim EB, Kim DS, Park SJ, et al. Hepatitis B virus reactivation in a surface antigen-negative and antibody-positive patient after rituximab plus CHOP chemotherapy. Cancer Res Treat 2008;40:36-38.
58. Moses SE, Lim ZY, Sudhanva M, et al. Lamivudine prophylaxis and treatment of hepatitis B virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab. J Med Virol 2006;78:1560-1563. (Pubitemid 44672497)
59. Iannitto E, Minardi V, Calvaruso G, et al. Hepatitis B virus reactivation and alemtuzumab therapy. Eur J Haematol 2005;74:254-258. (Pubitemid 40278496)
60. van der Kolk LE, Baars JW, Prins MH, et al. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 2002;100:2257-2259. (Pubitemid 35001266)
61. Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997;15:1567-1574. (Pubitemid 27167394)
62. Lazdina U, Alheim M, Nystrom J, et al. Priming of cytotoxic T cell responses to exogenous hepatitis B virus core antigen is B cell dependent. J Gen Virol 2003;84:139-146. (Pubitemid 36113559)
63. Ikeda K, Shiga Y, Takahashi A, et al. Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment. Leuk Lymphoma 2006;47:155-157. (Pubitemid 43101740)
64. Kang BW, Lee SJ, Moon JH, et al. Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review. Int J Hematol 2009;90:383-387.
65. Lakhani S, Davidson L, Priebat DA, et al. Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy. Hepatol Int 2008;2:498-499.
66. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
67. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
68. Shim JH, Park JW, Choi JI, et al. Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area. J Cancer Res Clin Oncol 2009;135:617-625.
69. Kim JW, Lee JO, Han SW, et al. Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy. Am J Clin Oncol, in press.
70. Chen L, Shiah HS, Chen CY, et al. Randomized, phase I, and pharmacokinetic (PK) study of RAD001, an mTOR inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC) [abstract]. J Clin Oncol 2009;27(Suppl 1):Abstract 4587.
71. Chen PM, Fan S, Liu CJ, et al. Changing of hepatitis B virus markers in patients with bone marrow transplantation. Transplantation 1990;49:708-713. (Pubitemid 20146950)
72. Seth P, Alrajhi AA, Kagevi I, et al. Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease. Bone Marrow Transplant 2002;30:189-194. (Pubitemid 34993859)
73. Dhedin N, Douvin C, Kuentz M, et al. Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. Transplantation 1998;66:616-619. (Pubitemid 28433844)
74. Onozawa M, Hashino S, Izumiyama K, et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 2005;79:616-619. (Pubitemid 40365894)
75. Knoll A, Boehm S, Hahn J, et al. Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 2004;33:925-929. (Pubitemid 38660126)
76. Fukushima N, Mizuta T, Tanaka M, et al. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol 2009;20:2013-2017.
77. Giaccone L, Festuccia M, Marengo A, et al. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2010;16:809-817.
78. Matsue K, Aoki T, Odawara J, et al. High risk of hepatitis B-virus reactivation after hematopoietic cell transplantation in hepatitis B core antibody-positive patients. Eur J Haematol 2009;83:357-364.
79. Perez-Grande R, Gutierrez-Zufiaurre N, Munoz-Criado S, et al. Hepatitis B reactivation in a hepatitis B surface antigen-negative patient after allogeneic bone marrow transplant: successful treatment with lamivudine and seroconversion. Diagn Microbiol Infect Dis 2009;64:80-82.
80. Beasley RP, Hwang LY, Lee GC, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983;2:1099-1102. (Pubitemid 14242389)
81. Ahn YO. Strategy for vaccination against hepatitis B in areas with high endemicity: focus on Korea. Gut 1996;38(Suppl 2):S63-66.
82. Katz LH, Fraser A, Gafter-Gvili A, et al. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepat 2008;15:89-102.
83. Martyak LA, Taqavi E, Saab S. Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis. Liver Int 2008;28:28-38.
84. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-2695. (Pubitemid 41007823)
85. Gauthier J, Bourne EJ, Lutz MW, et al. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. J Infect Dis 1999;180:1757-1762.
86. Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998;27:1670-1677. (Pubitemid 28264693)
87. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-1722. (Pubitemid 37500436)
88. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-1531.
89. Lee YC, Young KC, Su WC, et al. Emergence of YMDD mutant hepatitis B virus after allogeneic stem cell transplantation from a HBsAG-positive donor during lamivudine prophylaxis. Haematologica 2004;89:ECR09.
90. Pelizzari AM, Motta M, Cariani E, et al. Frequency of hepatitis B virus mutant in asymptomatic hepatitis B virus carriers receiving prophylactic lamivudine during chemotherapy for hematologic malignancies. Hematol J 2004;5:325-328. (Pubitemid 39214210)
91. Chan HL, Chui AK, Lau WY, et al. Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monoprophylaxis. Clin Transplant 2004;18:295-300. (Pubitemid 38744854)
92. Li YH, He YF, Jiang WQ, et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 2006;106:1320-1325.
93. Kim JS, Hahn JS, Park SY, et al. Long-term outcome after prophylactic lamivudine treatment on hepatitis B virus reactivation in non-Hodgkin's lymphoma. Yonsei Med J 2007;48:78-89. (Pubitemid 46403637)
94. Hui CK, Cheung WW, Au WY, et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 2005;54:1597-1603. (Pubitemid 41531779)
95. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005;352:2673-2681. (Pubitemid 41007822)
96. Tenney DJ, Rose RE, Baldick CJ, et al. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007;51:902-911. (Pubitemid 46355274)
97. Shibolet O, Ilan Y, Gillis S, et al. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 2002;100:391-396. (Pubitemid 34761098)
98. Idilman R, Arat M, Soydan E, et al. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J Viral Hepat 2004;11:141-147. (Pubitemid 38365765)
99. Lim LL, Wai CT, Lee YM, et al. Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients. Aliment Pharmacol Ther 2002;16:1939-1944. (Pubitemid 35253010)
100. Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred pre-emptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003;125:1742-1749. (Pubitemid 37500439)
101. Pinto PC, Hu E, Bernstein-Singer M, et al. Acute hepatic injury after the withdrawal of immunosuppressive chemotherapy in patients with hepatitis B. Cancer 1990;65:878-884. (Pubitemid 20063489)
102. Wong GC, Tan P, Goh YT, et al. Exacerbation of hepatitis in hepatitis B carriers following chemotherapy for haematological malignancies. Ann Acad Med Singapore 1996;25:500-503. (Pubitemid 26334454)
103. Lau JY, Lai CL, Lin HJ, et al. Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. Q J Med 1989;73:911-917. (Pubitemid 19256852)
104. Galbraith RM, Eddleston AL, Williams R, et al. Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 1975;2:528-530.
105. Ohtsu T, Sai T, Oka M, et al. Activation of hepatitis B virus infection by chemotherapy containing glucocorticoid in hepatitis B virus carriers with hematologic malignancies. Jpn J Clin Oncol 1991;21:360-365.
106. Dai MS, Wu PF, Shyu RY, et al. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int 2004;24:540-546. (Pubitemid 40028604)
107. Yeo W, Mok TS, Tse KK, et al. Phase II study of docetaxel and epirubicin in Chinese patients with metastatic breast cancer. Anticancer Drugs 2002;13:655-662. (Pubitemid 34816461)
108. Mok TS, Zee B, Chan AT, et al. A phase II study of gemcitabine plus oral etoposide in the treatment of patients with advanced nonsmall cell lung carcinoma. Cancer 2000;89:543-550. (Pubitemid 30640101)
109. Cheong K, Li J, Karapetis CS. Gemcitabine and reactivation of hepatitis B. Med Oncol 2003;20:385-388.
110. Grigg AP, Sasadeusz J. Hepatitis B reactivation after thalidomide. Intern Med J 2008;38:301-302. (Pubitemid 351465463)
111. Yeo W, Mok TS, Zee B, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005;97:1532-1538. (Pubitemid 41631953)
112. Persico M, De Marino F, Russo GD, et al. Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood 2002;99:724-725. (Pubitemid 34533120)
113. Lee GW, Ryu MH, Lee JL, et al. The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with non-Hodgkin's lymphoma who receive cytotoxic chemotherapy. J Korean Med Sci 2003;18:849-854.
114. Leaw SJ, Yen CJ, Huang WT, et al. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol 2004;83:270-275. (Pubitemid 38594322)
115. Ozguroglu M, Bilici A, Turna H, et al. Reactivation of hepatitis B virus infection with cytotoxic therapy in non-Hodgkin's lymphoma. Med Oncol 2004;21:67-72. (Pubitemid 38491332)
116. Yeo W, Chan PK, Ho WM, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004;22:927-934. (Pubitemid 41103605)